Fresenius and WuXi Biologics enter exclusive development agreement to expand biosimilars pipeline
Fresenius SE & Co. KGaA announced an exclusive development agreement with WuXi Biologics that gives Fresenius access to up to 37 identified biosimilar candidates over the next decade, potentially expanding its portfolio from 29 to up to 66 molecules. The agreement, the largest in the biosimilars industry to date, preserves Fresenius' full commercialization economics and strategic flexibility.
Primary source
Company press release (PR Newswire), November 2, 2026
Fresenius and WuXi Biologics enter exclusive development agreement to expand biosimilars pipeline
Read the source: Fresenius and WuXi Biologics enter exclusive development agreement to expand biosimilars pipeline prnewswire.com
Machine-summarized from the source above; not independently reported. How we use automation